Ms. Hollingsworth is one of the leaders of the entrepreneurial and life sciences communities and serves on various industry and community boards, including DS Biopharma, Talee Bio, the University City Science Center, the Kimmel Center for the Performing Arts, and Breastcancer.Org.
Dr. Lau earned an MBA from the Wharton School of Business at the University of Pennsylvania, a PhD in Neuroscience from the University of Cincinnati College of Medicine and a BS in Bioengineering from the University of Pennsylvania.
At Elan Pharmaceuticals, Mr. Bridy was responsible for out-licensing an oncology and neuroscience portfolio in addition to completing commercial diligence on internal and external investment opportunities in their Business Development group. At GlaxoSmithKline, Mr. Bridy was responsible for due diligence and valuation of select oncology in-licensing and pipeline drugs in the in their Global Commercial Strategy group. Mr. Bridy also served as Vice President of Strategy and Business Development at BTG plc. While at BTG, Mr. Bridy played a key role in the financing of two early stage pharmaceutical companies, Avera Pharmaceuticals and Senexis Ltd. In addition, Mr. Bridy co-founded and served as the CFO of a specialty pharmaceutical company, as well as founded a healthcare IT services company to better manage intelligence around drugs in development.
Mr. Bridy has an MA in Biology and an MBA in Finance from Villanova University. He has a BA and BS degree in Zoology from Miami University.
Eric was the Director of Clinical Research at Merck & Co., working on CNS and pain indications and later Vice President of Clinical Development at Johnson & Johnson. While at Johnson & Johnson D. Yuen served as the therapeutic area head for CNS and the head of clinical development at a monoclonal antibodies and vaccines joint venture between Johnson & Johnson and Elan. Eric later served as Chief Medical Officer for Ultragenyx, a start-up company focused on rare genetic diseases, and as VP Clinical Development at BioClin Therapeutics, a start-up focused on the rare genetic disorder achondroplasia (dwarfism) and bladder cancer. Eric continues to serve as a consultant to biotechnology and pharmaceutical companies.
Earlier in his career, Dr. Yuen was an assistant professor of neurology at the University of Washington where he conducted clinical research in rare disorders such as ALS and muscular dystrophies. Eric completed his undergraduate education at Stanford University, M.D. from the University of Chicago, Pritzker School of Medicine, neurology residency at UCSF, and a post-doc in the lab studying neurotrophic factor signaling at UCSF.
Prior to joining Militia Hill Ventures, Ms. D’Oyley-Gay was Vice President and Associate General Counsel at GlaxoSmithKline for 14 years, supporting GlaxoSmithKline’s global corporate strategy and business development groups. In 2009, Ms. D’Oyley-Gay received the Healthcare Businesswomen’s Association Rising Star Award for GlaxoSmithKline. Prior to joining GlaxoSmithKline, Ms. D’Oyley-Gay was in private practice, including at Reed Smith LLP, representing pharmaceutical companies and healthcare systems in transactional and healthcare regulatory matters, and at a boutique health law firm, representing physician practice groups and affiliated ventures.
Ms. D'Oyley-Gay obtained a Juris Doctorate Degree from the University of Pennsylvania Law School and a Bachelor of Science Degree in Economics from the University of Delaware.
B.A. received his AB in Human Development and Regenerative Biology and a secondary degree in Global Health and Health Policy from Harvard University. While at Harvard, B.A. conducted research in cardiac optogenetics and in post-traumatic cognitive development.
Matt received his BS in Neuroscience from Brown University. While at Brown, Matt conducted neurobiology research focused on plasticity in the spinal cord and was a varsity swimmer.